IRDM
RKLB
The analyst sugar rush
Rocket Lab didn’t just get a nod from Cantor Fitzgerald — it got the kind of nod that can send a stock hunting for its next caffeine hit. The firm reiterated its Overweight rating and slapped a $122 price target on RKLB, saying the company’s upcoming Neutron debut is the “most material catalyst.”
That’s analyst-speak for: this is the part of the story that could actually move the stock, not just keep the PowerPoint pretty.
Why Neutron matters
Cantor thinks Neutron, once it gets off the pad, could become a real alternative to SpaceX’s Falcon 9. That’s a big deal because Rocket Lab has long been more of a scrappy launch specialist than a full-on heavyweight. If Neutron works, the company’s addressable market gets a lot bigger — and so does the hype.
A few things are making bulls even chirpier:
- Rocket Lab just logged its 96th successful Electron launch
- The company says it has enough cash lined up to fund its Iridium acquisition
- Cantor says the combined business could roughly double annual revenue
The stock market does its thing
RKLB shares were already up nearly 2% in Tuesday premarket trading after jumping 8.24% on Monday. So yes, this is one of those classic “analyst note meets momentum trade” moments — the kind where traders pile in first and ask questions later.
The broader chart is still a little messy, though. The stock has climbed back above its shorter-term moving averages, but it’s still below key longer-term levels. Translation: the bounce is real, but the boss-level test is still ahead.
Big picture
For investors, the takeaway is simple: Rocket Lab is no longer just a moonshot pun. Between Neutron, the Iridium deal, and a stronger launch track record, the company is trying to graduate from “interesting space stock” to “actual platform with scale.” That’s the kind of story Wall Street likes to keep revisiting — especially when the stock starts acting like it believes it too.